| |
CTRCD (n = 13)
|
No CTRCD (n = 59)
|
p value
|
|---|
|
Age (years)
|
47.2 ± 7.7
|
49.2 ± 8.8
|
0.471
|
|
Hypertension (%)
|
2 (15.4)
|
10 (16.9)
|
1.000
|
|
ACEi or ARB use (%)
|
1 (7.7)
|
6 (10.2)
|
0.629
|
|
Beta-blocker use (%)
|
0 (0.0)
|
3 (5.1)
|
0.545
|
|
Diabetes mellitus (%)
|
1 (7.7)
|
4 (6.8)
|
1.000
|
|
Dyslipidemia (%)
|
2 (15.4)
|
5 (8.5)
|
0.602
|
|
Smoking (%)
|
1 (7.7)
|
2 (3.4)
|
0.455
|
|
BMI (kg/m2)
|
24.9 ± 4.5
|
23.8 ± 3.9
|
0.412
|
|
Epirubicin (%)
|
5 (38.5)
|
29 (49.2)
|
0.485
|
|
Epirubicin dose (mg/m2)
|
336.0 ± 68.4
|
314.5 ± 88.4
|
0.610
|
|
Doxorubicin (%)
|
5 (38.5)
|
16 (27.1)
|
0.504
|
|
Doxorubicin dose (mg/m2)
|
304.8 ± 38.3
|
266.6 ± 32.0
|
0.038
|
|
Cyclophosphamide (%)
|
8 (61.5)
|
38 (64.4)
|
1.000
|
|
Cyclophosphamide dose (mg/m2)
|
2550.0 ± 424.3
|
2460.0 ± 222.8
|
0.388
|
|
Docetaxel (%)
|
4 (30.8)
|
19 (32.2)
|
1.000
|
|
Docetaxel dose (mg/m2)
|
337.5 ± 75.0
|
331.6 ± 150.7
|
0.940
|
|
Radiation therapy (%)
|
7 (53.8)
|
27 (45.8)
|
0.597
|
|
Radiation dose (cGy)
|
5754.9 ± 398.8
|
5628.4 ± 362.3
|
0.426
|
- CTRCD: cancer therapeutics-related cardiac dysfunction, ACEi: angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blocker, BMI: body mass index
